Vertex Pharmaceuticals and Illumina Ventures both contributed to a round that increased the genetic therapeutics developer's total funding to over $300m.
US-based genetic medicine developer Arbor Biotechnologies closed its series B round at $215m on Tuesday, with genomics technology provider Illumina and pharmaceutical firm Vertex Pharmaceuticals among the investors.
Singapore state-owned investment firm Temasek co-led the round with healthcare investment group Ally Bridge and investment firm TCG Crossover while Illumina participated through its corporate venturing unit, Illumina Ventures.
Arrowmark Partners, Deep Track Capital, Great Point Ventures, Janus Henderson Investors, Logos Capital, Ono Venture Investment, Piper Heartland Healthcare Capital and Ridgeback Capital…
